科研之友
微信
新浪微博
Facebook
分享链接
摘要
Objective: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers. %26lt;br%26gt;Design: Double-blind, placebo-controlled clinical trial. %26lt;br%26gt;Setting: Academic medical centers. %26lt;br%26gt;Participants: Subjects with mild to moderate Alzheimer disease. %26lt;br%26gt;Intervention: Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (alpha-tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of alpha-lipoic acid (E/C/ALA); 400 mg of coenzyme Q 3 times/d; or placebo. %26lt;br%26gt;Main Outcome Measures: Changes from baseline to 16 weeks in CSF biomarkers related to Alzheimer disease and oxidative stress, cognition (Mini-Mental State Examination), and Alzheimer%26apos;s Disease Cooperative Study Activities of Daily Living Scale). %26lt;br%26gt;Results: Seventy-eight subjects were randomized; 66 provided serial CSF specimens adequate for biochemical analyses. Study drugs were well tolerated, but accelerated decline in Mini-Mental State Examination scores occurred in the E/C/ALA group, a potential safety concern. Changes in CSF A beta 42, tau, and P-tau(181) levels did not differ between the 3 groups. Cerebrospinal fluid F2-isoprostane levels, an oxidative stress biomarker, decreased on average by 19% from baseline to week 16 in the E/C/ALA group but were unchanged in the other groups. %26lt;br%26gt;Conclusions: Antioxidants did not influence CSF biomarkers related to amyloid or tau pathology. Lowering of CSF F2-isoprostane levels in the E/C/ALA group suggests reduction of oxidative stress in the brain. However, this treatment raised the caution of faster cognitive decline, which would need careful assessment if longer-term clinical trials are conducted.
- 出版日期2012-7
